Zusduri launch and new patents drive the UroGen story
- UroGen is a two-product commercial biotech with growing U.S. revenue from Jelmyto and Zusduri.
- Total revenue hit $72.5 million in the second quarter of 2026, up from $24.2 million a year ago.
- Zusduri generated $50.4 million in the second quarter as its permanent billing code helped doctors adopt the treatment.
- The company settled a patent lawsuit with Teva, which removes a major threat to Jelmyto.
- A new patent allowance extends intellectual property protection for Zusduri into 2044.
A launch that must keep working
UroGen's main bet is Zusduri. It is approved for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The company wants Zusduri to replace some repeat surgeries with local chemoablation, meaning medicine placed in the bladder to destroy tumor tissue.
The launch accelerated significantly in the second quarter of 2026. Zusduri revenue reached $50.4 million, representing 73 percent sequential growth. A new patent allowance also extends protection for Zusduri and the pipeline drug UGN-103 into 2044, improving the long-term outlook.
The pipeline matters because UroGen wants to extend the RTGel platform. UGN-103 is on track for an NDA submission in the third quarter of 2026. The company also settled patent litigation with Teva over Jelmyto, removing a major near-term risk that had worried investors.
The bear case is focused on costs and valuation. Management increased spending guidance to fund the Zusduri launch. The stock needs a smooth commercial ramp to justify that investment, especially with a low valuation score even after better sales momentum.
RTGel turns dwell time into a product
UroGen's platform is called RTGel. It is a reverse-thermal hydrogel, which means it is liquid when given and then turns into a gel at body temperature. The goal is simple: keep cancer medicine in contact with urinary tract tissue for longer.
The company makes money from U.S. product sales of Jelmyto and Zusduri. Jelmyto treats low-grade upper tract urothelial cancer. Zusduri treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is now the bigger near-term growth driver.
This model can scale if urologists use the drugs often and payers keep paying without delays. It can break if community practices avoid the workflow or if single-source suppliers fail to deliver key compounds.
UroGen also has financial room after a $250 million debt refinancing that pushed repayment to 2030 at an 8.25 percent fixed rate. That helps fund the launch, but it does not remove execution risk.
Two sold drugs, several shots
Zusduri
Zusduri is the main value driver. It was FDA-approved on June 12, 2025, and produced $50.4 million of second-quarter 2026 revenue. A new patent protects it into 2044.
Jelmyto
Jelmyto is approved for adults with low-grade upper tract urothelial cancer. It generated $22.0 million of revenue in the second quarter of 2026, and early generic risks are now mitigated by a settlement with Teva.
UGN-103
UGN-103 is a next-generation RTGel formulation. UroGen plans an NDA submission in the third quarter of 2026 and recently secured patent protection into 2044.
UGN-104
UGN-104 is another RTGel-based formulation in Phase 3. Enrollment is expected to complete in 2026.
UGN-501
UGN-501 is a next-generation investigational oncolytic virus, a virus designed to attack cancer cells. The FDA cleared its IND, and a Phase 1 trial is expected late in 2026.
UGN-201
UGN-201 is an immuno-uro-oncology pipeline candidate. It gives UroGen another early-stage shot beyond mitomycin-based RTGel drugs.
Revenue is still very concentrated
UroGen reports one operating segment. In the second quarter of 2026, Zusduri made up 70 percent of the $72.5 million total product revenue, with the remainder from Jelmyto.
What could break the thesis
Zusduri launch stalls while costs rise
High impact · Medium oddsThe company depends heavily on the Zusduri launch. Management increased operating expense guidance to accelerate investment in the drug. If community practice adoption slows or repeat utilization drops, revenue growth could stall while expenses remain high.
Community adoption is weaker than expected
High impact · Medium oddsThe permanent J-code removed a major payment barrier. Still, doctors must change office workflow and get comfortable using a new bladder treatment instead of repeat surgery. The mix moving toward community practices is important for scale.
UGN-103 development delays
Medium impact · Medium oddsUGN-103 is important because it extends the franchise and resets patent protection to 2044. The UTOPIA data reduce some risk, but an NDA still needs to be filed and reviewed. Any delay would weaken the bridge from current products to the next cycle.
Supplier concentration bites
Medium impact · Low oddsUroGen relies on single-source suppliers for key compounds. A supply issue could limit product availability right when the Zusduri launch needs clean execution. Small biotech supply chains can have little room for error.
In one breath
What does UroGen Pharma do?
UroGen develops and sells cancer treatments for the urinary tract. Its core technology, RTGel, helps medicine stay in contact with bladder or upper urinary tract tissue for longer.
Why is Zusduri important for URGN stock?
Zusduri is the main growth driver. It produced $50.4 million of second-quarter 2026 revenue and targets a market management says could be over $5.0 billion.
What is a J-code and why did it matter?
A J-code is a billing code used for drug reimbursement. Zusduri's permanent J-code became effective on January 1, 2026, which made it easier for doctors to use and get paid for the drug.
What is the biggest risk for UroGen?
The biggest risk is commercial execution. UroGen must keep Zusduri revenue growing and manage operating expenses to justify its ongoing investment.
